Ernexa Therapeutics Market Sentiment

Market sentiment signals for Ernexa Therapeutics (ERNA): analyst consensus, short interest, options flow and insider activity.

Key Signals

Analyst Consensus▲ Buy

Short Interest▼ 2.7% short float

Options Flow— N/A

Insider Activity— N/A

Analyst Consensus

Buy

1 analysts

Options Flow (P/C)

—

Avg Consensus PT

$30

+1392.5%

Highest Price Target

$30

+1392.5%

Brookline Capital

Lowest Price Target

$30

+1392.5%

Brookline Capital

Short Interest

2.7%

Rising — Bearish

Insider Activity (30d)

—

Short Interest — % of Float

Recent Analyst Actions

Date	Firm	Analyst & Accuracy	Upside / Downside	PT Change	Action	Rating
May 7, 2026	Brookline Capital	——	+1392.5%	$30	Initiate	Buy

Insider & Market Activity News

Stocks That Hit 52-Week Lows On Friday

On Friday, 63 companies hit new 52-week lows.

Benzinga Insights

What's Going On With Eterna Therapeutics Stock Today?

Eterna Therapeutics Inc (NASDAQ: ERNA) shares initially surged Wednesday morning on recent insider buying, but the stock pulled back shortly after the market open.

Adam Eckert

Eterna Therapeutics Director Charles Cherington Reported Purchase of 785,268 @ Avg Price of $1.18/Share in Form 4 Filing on Tuesday

Charles Gross

Eterna Therapeutics 10%+ Owner John Halpern Reported Purchase of 1,007,760 Shares @ Avg Price of $1.18/Share in Form 4 Filing on Monday

Charles Gross

Stocks That Hit 52-Week Lows On Friday

Friday's session saw 236 companies set new 52-week lows.

Benzinga Insights

Stocks That Hit 52-Week Lows On Tuesday

On Tuesday, 85 stocks hit new 52-week lows.

Benzinga Insights

Ernexa Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル